Alliqua Biomedical (NASDAQ:ALQA) shares traded on -7.99% below secure line and closed at $2.13. The stock exchanged hands 365691 shares versus average trading capacity of 912.9 Million shares. It has a market cap of $10.76 Million.
Wall Street analysts are predicting that Alliqua Biomedical (NASDAQ:ALQA) will report earnings per share of $0 in their quarterly report. For the current quarter Alliqua Biomedical (NASDAQ:ALQA) has high EPS estimates of $0 in contradiction of low EPS estimates of $0. However a year ago for the same quarter the company has reported $-2.3 EPS. Average estimation for the current quarter has been provided by 0 analysts.
Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. Earnings surprises can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time. Hence, it’s not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.
A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Alliqua Biomedical (NASDAQ:ALQA) reported $-2.6 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.71 by $-1.89 with surprise factor of -266.2%.
Alliqua Biomedical (NASDAQ:ALQA) has average revenue estimates of $5.38 Million, compared to low analyst estimates of $4.98 Million and high estimates of $4.98 Million for the current quarter. A total number of 1 analysts provided estimations over revenues. For the current year the company’s revenue estimates are $22 Million compared to low analyst estimates of $22 Million and high estimates of $22 Million according to the prediction of 1 analysts.
Taking a broader look at the analyst consensus, according to 1 analysts Alliqua Biomedical (NASDAQ:ALQA)’s price will reach at $2.8 during 52 weeks. Its minimum price target estimates has been figured out at $2.8 while the maximum price target forecast is established at $2.8.
On the other hand Alliqua Biomedical (NASDAQ:ALQA) has Relative Strength Index (RSI 14) of 50.1 along with Average True Range (ATR 14) of 0.36. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days) as suggested by J Welles Wilder. In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The average true range (ATR) is a measure of volatility introduced by Welles Wilder.
Consequently Alliqua Biomedical (NASDAQ:ALQA)’s weekly and monthly volatility is 12.94%, 17.39% respectively.